Literature DB >> 2360804

Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease?

E C Hirsch1, C Duyckaerts, F Javoy-Agid, J J Hauw, Y Agid.   

Abstract

A 54-year-old man with a 5-year history of Parkinson's disease was treated with and autograft of adrenal medulla into the right caudate nucleus and died 4 months after surgery. Postmortem examination revealed that the graft was necrotic. It consisted mainly of reticulin and collagen fibrosis without catecholaminergic cell bodies identified either by immunohistochemistry or by in situ hybridization with labeled human tyrosine hydroxylase (TH) cDNA probe. Sparse TH-immunoreactive fibers, which did not stain for dopamine-beta-hydroxylase (DBH), ran through the graft. In contrast, intense staining for these catecholaminergic markers was found in the untransplanted adrenal medulla. Densely packed TH-positive, DHB-negative fibers were found in a restricted zone of the host striatum at the periphery of the graft. This effect was selective since the density of other neurons was not modified. The present study describes an additional patient in whom adrenal medulla autotransplantation failed to improve the parkinsonian disability. It suggests, however, that adrenal medulla grafts may stimulate the sprouting of striatal dopaminergic fibers in a limited zone of the grafted striatum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360804     DOI: 10.1002/ana.410270615

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

1.  Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ.

Authors:  E F Espejo; M C Gonzalez-Albo; J P Moraes; F El Banoua; J A Flores; I Caraballo
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

2.  Delayed increase of tyrosine hydroxylase expression in rat nigrostriatal system after traumatic brain injury.

Authors:  Hong Qu Yan; Xiecheng Ma; Xiangbai Chen; Youming Li; Lifang Shao; C Edward Dixon
Journal:  Brain Res       Date:  2006-12-28       Impact factor: 3.252

3.  Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor.

Authors:  P E Batchelor; G T Liberatore; J Y Wong; M J Porritt; F Frerichs; G A Donnan; D W Howells
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

4.  Contemporaneous bilateral postero-ventral pallidotomy for early onset "juvenile type" Parkinson's disease. Case report.

Authors:  R P Iacono; R R Lonser; S Yamada
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

5.  Unfavorable outcome of adrenal medullary transplant for Parkinson's disease.

Authors:  L S Forno; J W Langston
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 6.  Evidence for plasticity of the dopaminergic system in parkinsonism.

Authors:  G A Donnan; D G Woodhouse; S J Kaczmarczyk; J E Holder; G Paxinos; P J Chilco; A J Churchyard; R M Kalnins; G C Fabinyi; F A Mendelsohn
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

Review 7.  Cell-based therapies for Parkinson disease—past insights and future potential.

Authors:  Roger A Barker; Janelle Drouin-Ouellet; Malin Parmar
Journal:  Nat Rev Neurol       Date:  2015-08-04       Impact factor: 42.937

Review 8.  Historical perspective of cell transplantation in Parkinson's disease.

Authors:  Alejandra Boronat-García; Magdalena Guerra-Crespo; René Drucker-Colín
Journal:  World J Transplant       Date:  2017-06-24

Review 9.  Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?

Authors:  Cristina Salado-Manzano; Unai Perpiña; Marco Straccia; Francisco J Molina-Ruiz; Emanuele Cozzi; Anne E Rosser; Josep M Canals
Journal:  Front Cell Neurosci       Date:  2020-08-11       Impact factor: 6.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.